Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

A new study conducted by researchers at Queen Elizabeth Hospital Birmingham in Birmingham, Great Britain, evaluated outcomes and toxicity associated with stereotactic radiotherapy in patients with ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...